Recruiting
Phase 1/2
EBV-AST Cell Injection for EBV-Associated Lymphoproliferative Disorders
Condition(s) studied
Epstein-Barr Virus-Associated Lymphoproliferative DisordersEBV-Positive Lymphoma
Investigational drug(s) / intervention(s)
EBV-AST Cell Injection
EBV-AST Cell Injection: EBV-AST is an Epstein-Barr virus (EBV) antigen-specific cytotoxic T-lymphocyte product generated by ex vivo stimulation and expansion of T cells using peptide-loaded dendritic cells. EBV-AST is administered by intravenous infusion every 2 weeks for up to 3 infusions at escalating dose levels (3×10\^5, 3×10\^6, or 3×10\^7 cells/kg per infusion), according to the protocol-defined dose-escalation design.
Study summary
This is an investigator-initiated, open-label, single-arm, dose-escalation exploratory study to evaluate the safety, tolerability, and preliminary efficacy of EBV-AST cell injection in adults with EBV-associated lymphoproliferative disorders, including post-transplant lymphoproliferative disease (PTLD) and EBV-positive lymphomas. Participants will receive EBV-AST cell infusions intravenously every 2 weeks for up to 3 infusions at escalating dose levels. The primary objective is to assess safety and determine a potential optimal biologically active dose. Secondary objectives include preliminary tumor response and EBV-related virologic outcomes, as well as cellular PK/PD.
Eligibility
Inclusion Criteria:
1. Able to understand and voluntarily sign written informed consent.
2. Age 18 to 75 years, inclusive.
3. HLA genotype matches at least one of the following: HLA-A02:01, HLA-A11:01, or HLA-A\*24:02.
4. Karnofsky Performance Status (KPS) ≥ 70.
5. Life expectancy ≥ 3 months.
6. Diagnosed with EBV-associated lymphoproliferative disorders, including:
7. EBV infection-associated post-transplant lymphoproliferative disorder (PTLD) that is relapsed/refractory after at least first-line standard therapy; or
8. EBV-associated lymphoma confirmed by histology and/or cytology with EBER positivity (ISH/FISH), with no standard treatment available or not suitable for standard therapy, including but not limited to: EBV-positive DLBCL, EBV-positive NK/T-cell lymphoma, EBV-positive Hodgkin lymphoma, EBV-positive Burkitt lymphoma, EBV-positive nodal TFH lymphoma (AITL type), and EBV-positive primary cutaneous T-cell lymphoma, meeting protocol-defined relapsed/refractory criteria.
9. Absolute lymphocyte count ≥ 0.8 × 10\^9/L (except for PTLD participants).
10. Adequate organ and bone marrow function per protocol-defined criteria.
11. Participants of childbearing potential agree to use highly effective contraception throughout the study; women of childbearing potential must have a negative pregnancy test at screening.
Exclusion Criteria:
1. Known hypersensitivity to the investigational product or its components.
2. Uncontrolled active graft-versus-host disease (GVHD) in PTLD participants.
3. Known primary immunodeficiency disorders (e.g., X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, chronic granulomatous disease, hyper-IgE syndrome).
4. Severe uncontrolled medical conditions that, in the investigator's judgment, make the participant unsuitable for enrollment.
5. Serious cardiac disease within 6 months prior to first infusion (e.g., myocardial infarction, severe/unstable angina, bypass surgery, NYHA class III-IV heart failure).
6. Chronic diseases requiring systemic immunosuppressants or systemic steroids (except local/inhaled steroids or physiologic replacement therapy).
7. History of other malignancy within the past 5 years, except carcinoma in situ (e.g., cervix, bladder, breast) or non-melanoma skin cancer.
8. Receipt of lymphocyte-based immunotherapy (e.g., CIK, DC, DC-CIK, LAK) within 3 months prior to consent.
9. Receipt of interferon or other targeted immunodeficiency drugs within 3 months prior to consent; prior high-dose IL-2 therapy.
10. Anti-cancer therapy within 14 days prior to consent (including chemotherapy or immunosuppressants/steroids); other cell therapy or live vaccines/attenuated vaccines or other investigational drugs within 28 days prior to consent; curative radiotherapy or major surgery within 4 weeks, or palliative local radiotherapy within 2 weeks prior to consent.
11. Prior immune therapy-associated ≥ Grade 3 immune-related adverse events (irAEs).
12. Unresolved toxicity from prior therapy \> Grade 1 (except alopecia any grade; peripheral sensory neuropathy ≤ Grade 2).
13. Uncontrolled psychiatric or neurologic disorders; drug abuse or alcohol dependence.
14. Positive HIV antibody; positive Treponema pallidum antibody; active hepatitis B (HBsAg and/or HBeAg positive with HBV-DNA above ULN) or active hepatitis C (HCV-Ab positive and HCV-RNA positive).
15. Uncontrolled severe active infection or contagious disease (excluding EBV infection).
16. Pregnant or breastfeeding women.
Primary outcome measure(s)
- Dose-Limiting Toxicities (DLTs) — From first infusion (Day 0) through Day 28
Number of participants experiencing dose-limiting toxicities (DLTs) within 28 days after the first EBV-AST cell infusion, as defined by protocol-specific criteria and graded according to NCI CTCAE v5.0.
- Safety: Incidence of Adverse Events — From first infusion (Day 0) through 12 months after first infusion
Number of participants with treatment-emergent adverse events (AEs), immune-related adverse events (irAEs), and serious adverse events (SAEs), graded according to NCI CTCAE v5.0, including clinically significant laboratory abnormalities.
- Recommended/Optimal Biologically Active Dose (OBD) — Up to 28 days after first infusion for DLT evaluation; overall dose decision through study completion
Recommended/optimal biologically active dose (OBD) of EBV-AST, determined based on the incidence of DLTs, overall safety profile, and tolerability across dose levels.
Trial sites (1)
| Facility | City | Region | Status |
|---|
| Chinese PLA General Hospital |
Beijing |
Beijing Municipality |
Recruiting |
More Daihong Liu trials in China
